A Phase I/II, Dose Finding and Optimization Study of [Lu-177]Lu-NeoB in Combination with Capecitabine in Patients with GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination with a CDK4/6 Inhibitor. (NeoB-Cap1)

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination with Durvalumab and Bevacizumab Therapy in People with Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)

Lu-177-DOTA-EB-TATE in Adult Patients with Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

POSLUMA® (F-18-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions

Open-label Study Comparing AAA817 versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [Lu-177]Lu-PSMA Targeted Therapy (PSMAcTION)

Pilot of F-18-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (Lu-177) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults with Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study (RADIODOSE)

Low PSMA SUV Boost (LPS-Boost): Intensified Lu-177-PSMA-617 Treatment for Patients with Metastatic Castrate-Resistant Prostate Cancer with Low PSMA Expressing Disease

A Phase II Study of AAA617 Alone and AAA617 in Combination with ARPI in Patients with PSMA PET Scan Positive CRPC (PSMACare)

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used with Targeted Radiation-based Treatment (Lutetium Lu-177 Dotatate), Compared to Lutetium Lu-177 Dotatate Alone for Metastatic Neuroendocrine Tumors